X-linked protoporphyria (XLP), a rare erythropoietic porphyria, results from terminal exon gain-of-function mutations in the ALAS2 gene causing increased ALAS2 activity and markedly increased erythrocyte protoporphyrin levels. Patients present with severe cutaneous photosensitivity and may develop liver dysfunction. XLP was originally reported as X-linked dominant with 100% penetrance in males and females. We characterized 11 heterozygous females from six unrelated XLP families and show markedly varying phenotypic and biochemical heterogeneity, reflecting the degree of X-chromsomal inactivation of the mutant gene. ALAS2 sequencing identified the specific mutation and confirmed heterozygosity among the females. Clinical history, plasma and erythrocyte protoporphyrin levels were determined. Methylation assays of the androgen receptor and zinc-finger MYM type 3 short tandem repeat polymorphisms estimated each heterozygotes X-chromosomal inactivation pattern. Heterozygotes with equal or increased skewing, favoring expression of the wild-type allele had no clinical symptoms and only slightly increased erythrocyte protoporphyrin concentrations and/or frequency of protoporphyrin-containing peripheral blood fluorocytes. When the wild-type allele was preferentially inactivated, heterozygous females manifested the disease phenotype and had both higher erythrocyte protoporphyrin levels and circulating fluorocytes. These findings confirm that the previous dominant classification of XLP is inappropriate and genetically misleading, as the disorder is more appropriately designated XLP.

X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria / V. Brancaleoni, M. Balwani, F. Granata, G. Graziadei, P. Missineo, V. Fiorentino, S. Fustinoni, M.D. Cappellini, H. Naik, R.J. Desnick, E. Di Pierro. - In: CLINICAL GENETICS. - ISSN 0009-9163. - 89:1(2016 Jan), pp. 20-26. [10.1111/cge.12562]

X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria

V. Brancaleoni
;
F. Granata;P. Missineo;V. Fiorentino;S. Fustinoni;M.D. Cappellini;
2016

Abstract

X-linked protoporphyria (XLP), a rare erythropoietic porphyria, results from terminal exon gain-of-function mutations in the ALAS2 gene causing increased ALAS2 activity and markedly increased erythrocyte protoporphyrin levels. Patients present with severe cutaneous photosensitivity and may develop liver dysfunction. XLP was originally reported as X-linked dominant with 100% penetrance in males and females. We characterized 11 heterozygous females from six unrelated XLP families and show markedly varying phenotypic and biochemical heterogeneity, reflecting the degree of X-chromsomal inactivation of the mutant gene. ALAS2 sequencing identified the specific mutation and confirmed heterozygosity among the females. Clinical history, plasma and erythrocyte protoporphyrin levels were determined. Methylation assays of the androgen receptor and zinc-finger MYM type 3 short tandem repeat polymorphisms estimated each heterozygotes X-chromosomal inactivation pattern. Heterozygotes with equal or increased skewing, favoring expression of the wild-type allele had no clinical symptoms and only slightly increased erythrocyte protoporphyrin concentrations and/or frequency of protoporphyrin-containing peripheral blood fluorocytes. When the wild-type allele was preferentially inactivated, heterozygous females manifested the disease phenotype and had both higher erythrocyte protoporphyrin levels and circulating fluorocytes. These findings confirm that the previous dominant classification of XLP is inappropriate and genetically misleading, as the disorder is more appropriately designated XLP.
ALAS2; Genotype-phenotype; X-chromosomal inactivation; X-linked protoporphyria
Settore MED/09 - Medicina Interna
gen-2016
17-feb-2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
Brancaleoni_et_al-2015-Clinical_Genetics.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 943.5 kB
Formato Adobe PDF
943.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Brancaleoni_et_al-2015-Clinical_Genetics.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 557.67 kB
Formato Adobe PDF
557.67 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/271098
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact